STEP UP published: semaglutide 7.2 mg pushes weight loss toward 20%

Results from STEP UP, a randomized, controlled phase 3b trial of once-weekly semaglutide 7.2 mg in adults with obesity, were published in The Lancet Diabetes & Endocrinology ^[1]. The higher weekly dose produced 18.7% weight loss under the treatment policy estimand and 20.7% under the trial product estimand, compared with 15.6% for the 2.4 mg dose, alongside more nausea and more dysesthesia (abnormal or unpleasant skin sensations) ^[1].

Semaglutide is the molecule in Ozempic, Wegovy and Rybelsus. The 2.4 mg weekly dose is the one studied for weight management in the original STEP program and used as the comparison arm here ^[1]. STEP UP tested whether going higher — 7.2 mg once weekly — pushes average weight loss closer to the roughly 20% mark that has become a benchmark in obesity drug development ^[1].

What the two numbers mean

The two different results for the same dose are not a contradiction. They are two ways of analyzing the same trial, and regulators ask for both.

The treatment policy estimand (18.7%) includes everyone who was randomized, counting their weight at the end regardless of whether they stopped the drug early or started another treatment ^[1]. It is closer to real-world results, where some people discontinue.

The trial product estimand (20.7%) estimates what happens if people stay on the assigned drug for the full study without interruption ^[1]. It answers a narrower question: how much can this dose do when taken as intended. The gap of about two percentage points between the two figures is typical of obesity trials, where dropouts and early discontinuations pull the average down.

Either way, the difference versus 2.4 mg is roughly three percentage points on the treatment policy measure — 18.7% versus 15.6% ^[1].

Side effects moved too

The published results note more nausea and more dysesthesia with the 7.2 mg dose ^[1]. Nausea is the most common side effect across GLP-1 medicines and tends to cluster during dose escalation. Dysesthesia — tingling, burning or altered sensation in the skin — is a less familiar finding in this drug class and is worth watching as more data emerge.

The summary information available here does not give the exact rates of nausea, dysesthesia, or serious adverse events in each group, nor does it give the number of participants, the trial length, discontinuation rates, or results in subgroups such as people with type 2 diabetes. Those details are in the full paper and are not yet reflected in the sources used for this story.

Why it matters for patients

The practical question STEP UP raises is about the trade-off between more weight loss and more side effects. Adding roughly three percentage points of average weight loss is meaningful for some people — particularly those who plateau on 2.4 mg — but the trial also reported more nausea and more dysesthesia at the higher dose ^[1]. Averages also hide wide variation: in obesity trials, some participants lose far more than the mean and some lose very little.

It is also important to be clear about availability. The sources here do not state whether the 7.2 mg dose has been submitted to or approved by the US Food and Drug Administration, or whether it would be sold under an existing brand name. Until a regulator acts, a higher dose studied in a trial is not the same as a dose available at a pharmacy. Insurance coverage for any higher-dose version is likewise unknown.

What happens next

The STEP UP paper was published on September 14, 2025, in The Lancet Diabetes & Endocrinology ^[1]. Next steps to watch include any regulatory filing or decision on a 7.2 mg dose, longer-term follow-up on tolerability, and how these numbers compare with tirzepatide (Mounjaro, Zepbound) and newer oral candidates such as orforglipron (Foundayo). None of those comparisons are made in the source used here.

Anyone weighing dose changes should discuss it with the clinician who prescribes their medication.